Immuneering (IMRX) Equity Ratio (2020 - 2024)
Immuneering has reported Equity Ratio over the past 5 years, most recently at 0.84 for Q3 2024.
- Quarterly results put Equity Ratio at 0.84 for Q3 2024, down 7.82% from a year ago — trailing twelve months through Sep 2024 was 0.84 (down 7.82% YoY), and the annual figure for FY2023 was 0.88, down 1.65%.
- Equity Ratio for Q3 2024 was 0.84 at Immuneering, down from 0.86 in the prior quarter.
- Over the last five years, Equity Ratio for IMRX hit a ceiling of 0.96 in Q3 2021 and a floor of 0.66 in Q2 2021.
- Median Equity Ratio over the past 5 years was 0.91 (2023), compared with a mean of 0.7.
- Biggest five-year swings in Equity Ratio: surged 259.91% in 2021 and later dropped 7.82% in 2024.
- Immuneering's Equity Ratio stood at 0.59 in 2020, then surged by 259.91% to 0.94 in 2021, then decreased by 4.06% to 0.9 in 2022, then decreased by 1.65% to 0.88 in 2023, then decreased by 4.64% to 0.84 in 2024.
- The last three reported values for Equity Ratio were 0.84 (Q3 2024), 0.86 (Q2 2024), and 0.89 (Q1 2024) per Business Quant data.